

Rev03
Update: Dec,14,2021

DATASHEET

FGF-19, Human

Cat. No.: Z02738

Product Introduction

Species	Human
Protein Construction	Expressed with an N-terminal Met. FGF-19 (Arg23-Lys216) Accession # O95750
Purity	> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC
Endotoxin Level	< 1 EU/μg of protein by LAL method
Biological Activity	Fully biologically active when compared to standard. The ED ₅₀ as determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 150.0 ng/ml, corresponding to a specific activity of > 6.7 × 10 ³ IU/mg.
Expression System	E. coli
Theoretical Molecular Weight	21.8 kDa
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Background

Target Background : Fibroblast growth factor 19 (FGF19) belongs to the large FGF family which has at least 23 members. All FGF family members are heparin binding growth factors with a core 120 amino acid (aa) FGF domain that allows for a common tertiary structure. FGFs are expressed during embryonic development and in restricted adult tissues. Four distinct but related classes of FGF receptors, FGF R1, 2, 3, and 4, exist. Unlike most FGFs which bind to and activate more than one FGF receptor, FGF19 is a specific ligand for FGF R4.

Synonyms : FGF19; Fibroblast Growth Factor-19

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.